Phaseline

Targets › GSH

GSH: drug programs, companies and trials

4 programs from 3 companies in 4 trials: 3 Phase 2, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout Feb 2027.

Open in Phaseline: the race on GSH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Emmanuelle Waubant, MD PhDN-acetyl cysteine
Glutathione (GSH) precursor with antioxidant properties
GSHPhase 2Multiple SclerosisFeb 2027
Weill Medical College of Cornell UniversityNAC 3600mg/day
Precursor for glutathione (GSH) synthesis; antioxidant and mucolytic agent that replenishe
GSHPhase 2Chronic Fatigue SyndromeApr 2027
Weill Medical College of Cornell UniversityNAC 900mg/day
Precursor for glutathione (GSH) synthesis; antioxidant and mucolytic agent that replenishe
GSHPhase 2Chronic Fatigue SyndromeApr 2027
Michio Hirano, MDN-Acetylcysteine
Glutathione precursor and antioxidant; increases brain glutathione levels
GSHPhase 1Mitochondrial Disease–

Conditions

Chronic Fatigue Syndrome (2) Multiple Sclerosis (1) Mitochondrial Disease (1)

Modalities

small molecule (4)

Companies

Weill Medical College of Cornell University (2) Emmanuelle Waubant, MD PhD (1) Michio Hirano, MD (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.